Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DYN101 in Pediatric Centronuclear Myopathy
NCT04743557Phase 2Withdrawn
- Sponsor
- Dynacure
- Start
- Jan 2024
- Primary completion
- Sep 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
A Phase 2 trial of DYN101 in centronuclear myopathy (CNM), sponsored by Dynacure. Planned start Jan 2024; status: withdrawn.
02
Drugs
DYN101
03
Conditions
centronuclear myopathy (CNM)
Beyond the preview
Go deeper on NCT04743557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04743557.